TortIntelMass tort tracker by Mass Tort Ad Agency

All torts

Ozempic and GLP-1 stomach injuries

MDL 3094, E.D. Pa., Judge Karen S. Marston

Cases are centralized before one judge for pretrial work.

Stage
Coordinated (MDL or JCCP)
Campaign window
Open
Coordination
MDL 3094
Court
E.D. Pa.
Judge
Karen S. Marston
Category
Drugs
Defendants
Novo Nordisk
Injuries
Gastroparesis, Ileus, Bowel Obstruction

Updated . Maintained by Jacob Malherbe.

New federal cases per week

35 new cases in the last 7 days. New dockets in E.D. Pa. naming the defendants, from CourtListener's public federal docket index. The outlined bar is the current week so far.

03060Week of Aug 17, 2026: 29 new casesAug 17Week of Aug 24, 2026: 28 new casesWeek of Aug 31, 2026: 43 new casesAug 31Week of Sep 7, 2026: 13 new casesWeek of Sep 14, 2026: 23 new casesSep 14Week of Sep 21, 2026: 29 new casesWeek of Sep 28, 2026: 27 new casesSep 28Week of Oct 5, 2026: 33 new casesWeek of Oct 12, 2026: 2 new cases (week in progress)Oct 12

Counts all new E.D. Pa. cases against Novo Nordisk or Eli Lilly, which covers both GLP-1 MDLs.

Jacob Score: 48

Litigation strength from 0 to 100. Last reviewed Jul 20, 2026. How it's set

  • Science
  • Momentum
  • Campaign
  • Timeline
  • Verdicts

What changed

  • Oct 29, 2026
    New study
    Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
    Endocrine. Arslan T
    PubMed (Endocrine)
  • Oct 28, 2026
    News
    US judge declines to block Lilly’s Zepbound ads in Novo false advertising case
    The Pharma Letter
  • Oct 27, 2026
    News
    Courts Take On Lilly GLP-1 Ads, J&J Mesothelioma Trial, More
    Law360
  • Oct 16, 2026
    News
    OZEMPIC WARNING: Maryland Man Says Popular Diabetes Drug Left Him Permanently Blind, Files Lawsuit
    The Yeshiva World
  • Sep 10, 2026
    Case event
    Live hearings on the parties' expert testimony in the stomach injury MDL were scheduled for September 10 to 18, 2026. No bellwether trial date had been set.
    thomasabraunrph.substack.com
  • Jul 2, 2026
    Case event
    Judge Marston ordered that the NAION cases first decide two issues for all cases: whether GLP-1 drugs can cause NAION, and whether federal law preempts the warning claims.
    lawsuit-information-center.com
  • Jul 1, 2026
    Case event
    3,848 lawsuits were pending in the GLP-1 stomach injury MDL and 146 in the NAION vision loss MDL. No global settlement had been announced.
    lawsuit-information-center.com
  • Dec 15, 2025
    Case event
    The JPML created a separate MDL, No. 3163, for vision loss claims (NAION) linked to GLP-1 drugs, also assigned to Judge Marston.
    shouselaw.com
  • Aug 18, 2025
    Case event
    Judge Marston refused to dismiss 12 of the 17 counts against Novo Nordisk and Eli Lilly, while dismissing the design defect and medical monitoring claims.
    verusllc.com
  • Aug 15, 2025
    Case event
    Judge Marston ruled that plaintiffs claiming gastroparesis need a gastric emptying study in their records to support the diagnosis.
    tavrn.ai
  • Feb 2, 2024
    Case event
    The JPML created MDL No. 3094 in the Eastern District of Pennsylvania for lawsuits alleging GLP-1 drugs such as Ozempic, Wegovy and Mounjaro caused gastroparesis and other stomach and bowel injuries. Defendants are Novo Nordisk and Eli Lilly.
    webiis08.mondaq.com

Watch this tort

Get Ozempic developments at the top of the Monday briefing.

Who typically qualifies

3+ months use · Gastroparesis or Ileus · Hospitalization

From campaign criteria. Qualification depends on each firm's review.

Related torts

Advertising on Ozempic?

Mass Tort Ad Agency runs Meta tort campaigns for plaintiff firms and can show you what this tort's audience looks like.

Talk to Mass Tort Ad Agency